PURPOSE: Oncology clinical trials (OCTs) are crucial in evaluating new cancer treatments, but only 2% to 3% of US adult patients with cancer enter OCTs. This study assessed barriers to participation in clinical trials among oncologists in a large integrated health care delivery system with an active clinical trials program. Although many studies have identified major physician barriers to enrollment, few have examined how these barriers affect actual trial accrual. METHODS: Using information from a mailed survey, we examined the effect of oncologists' attitudes, beliefs, experiences, sociodemographic factors, and practice characteristics on clinical trial accrual in the 2 years following the survey. We identified relationships between these variables and subsequent clinical trial accrual using correlations and mixed effects models. RESULTS: A construct combining questions that assessed oncologist attitudes, beliefs, and experiences substantially influenced OCT enrollment (r = .51; P < .0001). This construct included awareness of open clinical trials and specific eligible patients, as well as the practice of initiating a discussion about OCTs with most eligible patients. This broad concept of awareness had the greatest correlation with enrollment and mediated the effect on enrollment of other values and beliefs, such as welcoming a patient's initiation of a trial discussion and valuing the support of research nurses and coordinators. CONCLUSION: Even in a health care setting with an active clinical trials program, substantial research personnel, infrastructure support, and widespread access to trials among oncologists and patients, oncologists' participation remains quite variable. Oncologist values, beliefs, and awareness of clinical trials play an important role in OCT accrual.
PURPOSE: Oncology clinical trials (OCTs) are crucial in evaluating new cancer treatments, but only 2% to 3% of US adult patients with cancer enter OCTs. This study assessed barriers to participation in clinical trials among oncologists in a large integrated health care delivery system with an active clinical trials program. Although many studies have identified major physician barriers to enrollment, few have examined how these barriers affect actual trial accrual. METHODS: Using information from a mailed survey, we examined the effect of oncologists' attitudes, beliefs, experiences, sociodemographic factors, and practice characteristics on clinical trial accrual in the 2 years following the survey. We identified relationships between these variables and subsequent clinical trial accrual using correlations and mixed effects models. RESULTS: A construct combining questions that assessed oncologist attitudes, beliefs, and experiences substantially influenced OCT enrollment (r = .51; P < .0001). This construct included awareness of open clinical trials and specific eligible patients, as well as the practice of initiating a discussion about OCTs with most eligible patients. This broad concept of awareness had the greatest correlation with enrollment and mediated the effect on enrollment of other values and beliefs, such as welcoming a patient's initiation of a trial discussion and valuing the support of research nurses and coordinators. CONCLUSION: Even in a health care setting with an active clinical trials program, substantial research personnel, infrastructure support, and widespread access to trials among oncologists and patients, oncologists' participation remains quite variable. Oncologist values, beliefs, and awareness of clinical trials play an important role in OCT accrual.
Authors: Mollie W Howerton; M Chris Gibbons; Charles R Baffi; Tiffany L Gary; Gabriel Y Lai; Shari Bolen; Jon Tilburt; Teerath Peter Tanpitukpongse; Renee F Wilson; Neil R Powe; Eric B Bass; Jean G Ford Journal: Cancer Date: 2007-02-01 Impact factor: 6.860
Authors: Warren B Sateren; Edward L Trimble; Jeffrey Abrams; Otis Brawley; Nancy Breen; Leslie Ford; Mary McCabe; Richard Kaplan; Malcolm Smith; Richard Ungerleider; Michaele C Christian Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: Simon J Craddock Lee; Caitlin C Murphy; Ann M Geiger; David E Gerber; John V Cox; Rasmi Nair; Celette Sugg Skinner Journal: J Clin Oncol Date: 2019-06-05 Impact factor: 44.544
Authors: Lillian Chen; Jackelyn B Payne; Kaylin V Dance; Conner B Imbody; Cathy D Ho; Amy A Ayers; Christopher R Flowers Journal: Clin Lymphoma Myeloma Leuk Date: 2019-10-19
Authors: Monica Khunger; Sagar Rakshit; Adrian V Hernandez; Vinay Pasupuleti; Kate Glass; Matthew D Galsky; Petros Grivas Journal: Oncologist Date: 2018-08-01
Authors: Lena E Winestone; Kelly D Getz; Pooja Rao; Yimei Li; Matt Hall; Yuan-Shung V Huang; Alix E Seif; Brian T Fisher; Richard Aplenc Journal: Leuk Lymphoma Date: 2019-02-07
Authors: Sandra E Brooks; Carolyn Y Muller; William Robinson; Eleanor M Walker; Kate Yeager; Elise D Cook; Sue Friedman; Carol P Somkin; Carol Leslie Brown; Worta McCaskill-Stevens Journal: J Oncol Pract Date: 2015-10-13 Impact factor: 3.840
Authors: Shoshana M Rosenberg; Shari Gelber; Richard D Gelber; Ethan Krop; Larissa A Korde; Olivia Pagani; Ann H Partridge Journal: J Adolesc Young Adult Oncol Date: 2017-07-07 Impact factor: 2.223
Authors: Ryan D Nipp; Hang Lee; Elizabeth Powell; Nicole E Birrer; Emily Poles; Daniel Finkelstein; Karen Winkfield; Sanja Percac-Lima; Bruce Chabner; Beverly Moy Journal: Oncologist Date: 2016-03-14
Authors: Stéphane M Meystre; Paul M Heider; Youngjun Kim; Daniel B Aruch; Carolyn D Britten Journal: Int J Med Inform Date: 2019-05-23 Impact factor: 4.730
Authors: Andrew R Wong; Virginia Sun; Kevin George; Jennifer Liu; Simran Padam; Brandon A Chen; Thomas George; Arya Amini; Daneng Li; Mina S Sedrak Journal: JCO Oncol Pract Date: 2020-04-02